Jonathan Pell, MD | |
12605 E 16th Ave, Aurora, CO 80045-2545 | |
(720) 848-0000 | |
Not Available |
Full Name | Jonathan Pell |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 20 Years |
Location | 12605 E 16th Ave, Aurora, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1457424681 | NPI | - | NPPES |
03770338 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 45854 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Colorado Hospital Authority | Aurora, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Physicians Incorporated | 3476465667 | 2657 |
News Archive
There is still a lot to learn about coronavirus disease (COVID-19), which is currently ravaging across the globe. Though scientists are slowly gaining a better understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is still unclear if being infected once may provide long-lasting immunity against the novel coronavirus.
Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011.
A paper published online today in Nature reveals that glia play a key role in preventing the progression of the most prominent Rett Syndrome symptoms displayed by mouse models of the disease: lethality, irregular breathing and apneas, hypoactivity and decreased dendritic complexity.
ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).
› Verified 1 days ago
Entity Name | University Physicians Incorporated |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
There is still a lot to learn about coronavirus disease (COVID-19), which is currently ravaging across the globe. Though scientists are slowly gaining a better understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is still unclear if being infected once may provide long-lasting immunity against the novel coronavirus.
Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011.
A paper published online today in Nature reveals that glia play a key role in preventing the progression of the most prominent Rett Syndrome symptoms displayed by mouse models of the disease: lethality, irregular breathing and apneas, hypoactivity and decreased dendritic complexity.
ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Jonathan Pell, MD Po Box 876, Aurora, CO 80040-0876 Ph: (303) 493-7000 | Jonathan Pell, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
There is still a lot to learn about coronavirus disease (COVID-19), which is currently ravaging across the globe. Though scientists are slowly gaining a better understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is still unclear if being infected once may provide long-lasting immunity against the novel coronavirus.
Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011.
A paper published online today in Nature reveals that glia play a key role in preventing the progression of the most prominent Rett Syndrome symptoms displayed by mouse models of the disease: lethality, irregular breathing and apneas, hypoactivity and decreased dendritic complexity.
ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).
› Verified 1 days ago
Dr. Martin W Rausch, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 2550 S Parker Rd, Aurora, CO 80014 Phone: 303-338-4545 | |
Peter Boulos, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 303-724-5524 | |
John Watson Iv, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Thuy-quynh Jennifer Le, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 13001 E 17th Pl, Aurora, CO 80045 Phone: 303-724-6595 | |
Hillary L Western, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Dr. Hemali P Patel, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12401 E 17th Ave, Suite 450b Mail Stop F-782, Aurora, CO 80045 Phone: 720-848-4289 Fax: 720-848-4293 | |
Madison Hibshman, Hospitalist Medicare: Medicare Enrolled Practice Location: 13001 E 17th Pl, Aurora, CO 80045 Phone: 303-724-1784 |